Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Tanvetyanon
Tawee
T
D000700:Analgesics / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000150:complications / Q000517:prevention & control* / Q000556:secondary; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D050723:Fractures, Bone / Q000139:chemically induced / Q000150:complications; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007568:Jaw / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009336:Necrosis / Q000139:chemically induced / Q000150:complications; D010019:Osteomyelitis / Q000139:chemically induced / Q000150:complications; D010022:Osteopetrosis / Q000139:chemically induced / Q000150:complications; D010146:Pain / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D010147:Pain Measurement; D000077268:Pamidronate; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D011788:Quality of Life; D012107:Research Design / Q000592:standards; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D000700:Analgesics; D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate